Six Novel Nonsynonymous CYP1A2 Gene Polymorphisms: Catalytic Activities of the Naturally Occurring Variant Enzymes

Journal of Pharmacology and Experimental Therapeutics

Volumn 308, Issue 1, 2004, Pages 300-306

  Murayama, Norie ^a   Soyama, Akiko ^a   Saito, Yoshiro ^a   Nakajima, Yukiko ^a   Komamura, Kazuo ^b   Ueno, Kazuyuki ^b   Kamakura, Shiro ^b   Kitakaze, Masafumi ^b   Kimura, Hideo ^c   Goto, Yu Ichi ^c   Saitoh, Osamu ^d   Katoh, Masaaki ^d   Ohnuma, Teiichi ^d   Kawai, Mitsuru ^d   Sugai, Kenji ^d   Ohtsuki, Taisuke ^d   Suzuki, Chieko ^d   Minami, Narihiro ^c,d   Ozawa, Shogo ^a   Sawada, Jun Ichi ^a  

^a NATIONAL INSTITUTE OF HEALTH SCIENCES   (Japan)

^b NATIONAL CEREBRAL AND CARDIOVASCULAR CENTER   (Japan)

^c NATIONAL INSTITUTE OF NEUROSCIENCE   (Japan)

^d NATIONAL INSTITUTE OF MENTAL HEALTH   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

CYTOCHROME P450 1A2; DNA; ETHOXYRESORUFIN; ETHOXYRESORUFIN DEETHYLASE; PHENACETIN; PHENYLALANINE;

ANIMAL CELL; ARTICLE; CATALYSIS; CELL STRAIN V 79; CONTROLLED STUDY; DNA POLYMORPHISM; ELECTROPHORESIS; GENETIC TRANSFECTION; HETEROZYGOSITY; IMMUNOBLOTTING; JAPAN; MICROSOME; NONHUMAN; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; SINGLE NUCLEOTIDE POLYMORPHISM; SITE DIRECTED MUTAGENESIS;

AMINO ACID SEQUENCE; ANIMALS; CELLS, CULTURED; CRICETINAE; CYTOCHROME P-450 CYP1A2; HUMANS; KINETICS; MOLECULAR SEQUENCE DATA; MUTAGENESIS, SITE-DIRECTED; OXAZINES; PHENACETIN; POLYMORPHISM, GENETIC; POLYMORPHISM, SINGLE NUCLEOTIDE; SEQUENCE HOMOLOGY, AMINO ACID; SUBSTRATE SPECIFICITY; TRANSFECTION;

EID: 9144230034     PISSN: 00223565     EISSN: None     Source Type: Journal    
DOI: 10.1124/jpet.103.055798     Document Type: Article

References (33)

1. Butler MA, Lang NP, Young JF, Caporaso NE, Vineis P, Hayes RB, Teitel CH, Massengill JP, Lawsen MF, and Kadlubar FF (1992) Determination of CYP1A2 and NAT2 phenotypes in human populations by analysis of caffeine urinary metabolites. Pharmacogenetics 2:116-127.
2. Chevalier D, Cauffiez C, Allorge D, Lo-Guidice JM, Lhermitte M, Lafitte JJ, and Broly F (2001) Five novel natural allelic variants-951A>C, 1042G>A (D348N), 1156A>T (I386F), 1217G>A (C406Y) and 1291C>T (C431Y)-of the human CYP1A2 gene in a French Caucasian population. Hum Mutat 17:355-356.
3. Chida M, Yokoi T, Fukui T, Kinoshita M, Yokota J, and Kamataki T (1999) Detection of three genetic polymorphisms in the 5′-flanking region and intron 1 of human CYP1A2 in the Japanese population. Jpn J Cancer Res 90:899-902.
4. Code EL, Crespi CL, Penman BW, Gonzalez FJ, Chang TKH, and Waxman DJ (1997) Human cytochrome P4502B6. Interindividual hepatic expression, substrate specificity, and role in procarcinogen activation. Drug Metab Dispos 25:985-993.
5. Eaton DL, Gallagher EP, Bammler TK, and Kunze KL (1995) Role of cytochrome P4501A2 in chemical carcinogenesis: implications for human variability in expression and enzyme activity. Pharmacogenetics 5:259-274.
6. Fuhr U, Doehmer J, Battula N, Wolfel C, Kudla C, Keita Y, and Staib AH (1992) Biotransformation of caffeine and theophynine in mammalian cell lines genetically engineered for expression of single cytochrome P450 isoforms. Biochem Pharmacol 43:225-235.
7. Gotoh O (1992) Substrate recognition sites in cytochrome P450 family 2 (CYP2) proteins inferred from comparative analyses of amino acid and coding nucleotide sequences. J Biol Chem 267:83-90.
8. Graham-Lorence S and Peterson JA (1996) P450s: structural similarities and functional differences. FASEB J 10:206-214.
9. Guengerich FP (1995) Structure, mechanism and biochemistry, in Cytochrome P450 (Oritz de Montellano PR ed) pp 473-535, Plenum Press, New York.
10. Hammons GJ, Yan-Sanders Y, Jin B, Blann E, Kadlubar FF, and Lyn-Cook BD (2001) Specific site methylation in the 5′-flanking region of CYP1A2 interindividual differences in human livers. Life Sci 69:839-845.
11. Hines RN and McCarver DG (2002) The ontogeny of human drug-metabolizing enzymes: phase I oxidative enzymes. J Pharmacol Exp Ther 300:355-360.
12. Huang JD, Guo WC, Lai MD, Guo YL, and Lambert GH (1999) Detection of a novel cytochrome P-450 1A2 polymorphism (F21L) in Chinese. Drug Metab Dispos 27:98-101.
13. Kivisto KT and Kroemer HK (1997) Use of probe drugs as predictors of drug metabolism in humans. J Clin Pharmacol 37 (1 Suppl):40S-48S.
14. Landi MT, Sinha R, Lang NP, and Kadlubar FF (1999) Human cytochrome P4501A2. IARC Sci Publ 148:173-195.
15. Leclercq I, Desager JP, Vandenplas C, and Horsmans Y (1996) Fast determination of low-level cytochrome P-450 1A1 activity by high-performance liquid chromatography with fluorescence or visible absorbance. J Chromatogr B Biomed Appl 681: 227-232.
16. Lewis DFV, Lake BG, George SG, Dicking M, Eddershaw PJ, Tarbit MH, Beresford AP, Goldfarb PS, and Guengerich FP (1999) Molecular modeling of CYP1 family enzymes CYP1A1, CYP1A2, CYP1A6 and CYP1B1 based on sequence homology with CYP102. Toxicology 139:33-79.
17. Lewis DFV (2002) Molecular modeling of human cytochrome P450-substrate interactions. Drug Metab Rev 34:55-67.
18. Lewis DFV, Lake BG, Dickins M, Ueng YF, and Goldfarb PS (2003) Homology modelling of human CYP1A2 based on the CYP2C5 crystallographic template structure. Xenobiotica 33:239-254.
19. Matter R, Alexandrino AM, and Laudanna AA (1999) Infrequent p53 gene alterations in ulcerative colitis. Braz J Med Biol Res 32:1083-1088.
20. Murayama N, Nakamura T, Saeki M, Soyama A, Saito Y, Sai K, Ishida S, Nakajima O, Itoda M, Ohno Y, et al. (2002) CYP3A4 gene polymorphisms influence testosterone 6β-hydroxylation. Drug Metab Pharmacokinet 17:150-156.
21. Nakajima M, Yokoi T, Mizutani M, Kinoshita M, Funayama M, and Kamataki T (1999) Genetic polymorphism in the 5′-flanking region of human CYP1A2 gene: effect on the CYP1A2 inducibility in humans. J Biochem 125:803-808.
22. Nakajima M, Yokoi T, Mizutani M, Shin S, Kadlubar FF, and Kamataki T (1994) Phenotyping of CYP1A2 in Japanese population by analysis of caffeine urinary metabolites: absence of mutation prescribing the phenotype in the CYP1A2 gene. Cancer Epidemiol Biomarkers Prev 3:413-421.
23. Parikh A, Josephy PD, and Guengerich FP (1999) Selection and characterization of human cytochrome P450 1A2 mutants with altered catalytic properties. Biolchemistry 38:5283-5289.
24. 1) relaxation measurements. Arch Biochem Biophys 384:47-58.
25. Rendic S (2002) Summary of information on human CYP enzymes: human P450 metabolism data. Drug Metab Rev 34:83-448.
26. Rodrigues AS, Silva ID, Caria MH, Laires A, Chaveca T, Glatt HR, and Rueff J (1994) Genotoxicity assessment of aromatic amines and amides in genetically engineered V79 cells. Mutat Res 341:93-100.
27. Sachse C, Brockmoller J, Bauer S, and Roots I (1999) Functional significance of a C→A polymorphism in intron 1 of the cytochrome P450 CYP1A2 gene tested with caffeine. Br J Clin Pharmacol 47:445-449.
28. Schmalix WA, Lang D, Schneider A, Bocker R, Greim H, and Doehmer J (1996) Stable expression and coexpression of human cytochrome P450 oxidoreductase and cytochrome P450 1A2 in V79 Chinese hamster cells: sensitivity to quinones and biotransformation of 7-alkoxyresorufins and triazines. Drug Metab Dispos 24: 1314-1319.
29. Scordo MG and Spina E (2002) Cytochrome P450 polymorphism and response to antipsychotic therapy. Pharmacogenomics 3:201-218.
30. Shimada T, Yamazaki H, Mimura M, Inui Y, and Guengerich FP (1994) Interindividual variations in human liver cytochrome P-450 enzymes involved in the oxidation of drugs, carcinogens, and toxic chemicals: studies with liver microsomes of 30 Japanese and 30 Caucasians. J Pharmacol Exp Ther 270:414-423.
31. 218 mutations of cytochrome P450 1A2 remarkably enhance hemolytic O-O cleavage of alkyl hydroperoxides. J Biol Chem 269:13296-13304.
32. Urban P, Jobert AS, Laine R, and Pompon D (2001) Cytochrome P450 (CYP) mutants and substrate-specificity alterations: segment-directed mutagenesis applied to human CYP1A1. Biochem Soc Trans 29:128-135.
33. Welfare MR, Aitkin M, Bassendine MF, and Daly AK (1999) Detailed modeling of caffeine metabolism and examination of the CYP1A2 gene: lack of a polymorphism in CYP1A2 in Caucasians. Pharmacogenetics 9:367-375.